In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Association of actigraphy-measured sleep parameters and subclinical atherosclerotic burden: the PESA study
2018

Congress : ESC Congress

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention - Cardiovascular Risk Assessment
  • Session type : Best Posters
  • FP Number : P2466

Authors : F Dominguez Rodriguez (Madrid,ES), JM Fernandez Alvira (Madrid,ES), L Fernandez Friera (Madrid,ES), B Lopez-Melgar (Madrid,ES), R Blanco-Rojo (Madrid,ES), A Fernandez-Ortiz (Madrid,ES), P Garcia-Pavia (Madrid,ES), JM Sanz (New York,US), JM Mendiguren (Madrid,ES), B Ibanez (Madrid,ES), H Bueno (Madrid,ES), V Fuster (Madrid,ES), E Lara-Pezzi (Madrid,ES), JM Ordovas (Madrid,ES)

15 views

Authors:
F. Dominguez Rodriguez1 , J.M. Fernandez Alvira2 , L. Fernandez Friera3 , B. Lopez-Melgar4 , R. Blanco-Rojo5 , A. Fernandez-Ortiz6 , P. Garcia-Pavia7 , J.M. Sanz8 , J.M. Mendiguren9 , B. Ibanez10 , H. Bueno11 , V. Fuster12 , E. Lara-Pezzi13 , J.M. Ordovas14 , 1University Hospital Puerta de Hierro Majadahonda, National Centre for Cardiovascular Research (CNIC). CIBERCV - Madrid - Spain , 2National Centre for Cardiovascular Research (CNIC) - Madrid - Spain , 3National Centre for Cardiovascular Research (CNIC), CIBERCV.HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM-CIEC, Madrid, Spain - Madrid - Spain , 4National Centre for Cardiovascular Research (CNIC), HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM-CIEC, Madrid, Spain - Madrid - Spain , 5IMDEA Food Institute, CEI UAM + CSIC - Madrid - Spain , 6National Centre for Cardiovascular Research (CNIC), CIBERCV. Universidad Complutense.Cardiovascular Institute, IDSSC, Hospital Clínico San Carlos - Madrid - Spain , 7University Hospital Puerta de Hierro Majadahonda, CIBERCV. Faculty of Health Sciences, University Francisco de Vitoria (UFV) - Madrid - Spain , 8Mount Sinai School of Medicine, Zena and Michael A. Wiener Cardiovascular Institute. CNIC (Madrid) - New York - United States of America , 9Banco de Santander - Madrid - Spain , 10National Centre for Cardiovascular Research (CNIC), CIBERCV, IIS-Fundaciόn Jiménez Díaz Hospital - Madrid - Spain , 11National Centre for Cardiovascular Research (CNIC), Cardiology Department, Hospital Universitario 12 de Octubre.Universidad Complutense de Madrid - Madrid - Spain , 12National Centre for Cardiovascular Research (CNIC), Zena and Michael A. Wiener Cardiovascular Institute. Icahn School of Medicine Mount Sinai, New York - Madrid - Spain , 13National Centre for Cardiovascular Research (CNIC), CIBERCV - Madrid - Spain , 14National Centre for Cardiovascular Research (CNIC), IMDEA Food Institute, CEI UAM + CSIC,U.S. Dept of Agriculture HNRCA. Tufts University, Boston, US - Madrid - Spain ,

On behalf: PESA study

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 474-475

Background: Both short and long sleep duration, as well as poor quality of sleep have been associated with an increased risk of cardiovascular disease. However, big studies evaluating objectively measured sleep parameters and subclinical atherosclerosis assessed by multimodality imaging approach are still lacking.

Objectives: To evaluate the association of actigraphy-measured sleep parameters with subclinical atherosclerosis in a large asymptomatic middle-aged population included in the PESA (Progression of Early Subclinical Atherosclerosis) study. Moreover, to investigate possible interactions between sleep parameters and conventional risk factors, psychosocial characteristics, dietary habits, inflammatory and aging markers.

Methods: A total of 3974 PESA study participants (mean age 45.8±4.3; 62.6% men) underwent actigraphic recording during one week. Four groups were defined according to sleep duration: 1) and 2) Participants with short sleep duration (SSD) (below 6h and 6–7h); 3) Reference group with 7–8h of sleeping; 4) Participants with long sleep duration (above 8h). Additionally, the cohort was divided into five quintiles taking into account quality of sleep (Fragmentation Index (FI)). Medical history data, blood tests and dietary habits were included. 3D vascular ultrasound (VUS) and coronary computed tomography (CT) were performed to quantify noncoronary atherosclerosis and coronary calcification, respectively.

Results: Sleep duration below 6 h was independently associated with a higher atherosclerotic burden and more affected vascular territories measured with 3D VUS compared to reference group (OR: 1.19, CI 95%: 1.00–1.42; p=0.05 and OR: 1.23, CI 95%: 1.03–1.47; p=0.02, respectively). Participants with a more fragmented sleep (Quintile 5; FI: 7.39–43.43) also presented a higher risk towards more affected territories (adjusted OR: 1.35, CI 95%: 1.05–1.65; p=0.01). Coronary calcification was not independently associated with sleep parameters. No differences were observed regarding inflammation and aging biomarkers and sleep parameters. However, SSD-participants presented more frequently with metabolic syndrome (MetS).

Conclusions: Actigraphy measured SSD and fragmented sleep are associated with an increased risk of noncoronary atherosclerosis and a higher prevalence of MetS. These findings show that sleep is associated with cardiovascular health and suggest that the modification of abnormal sleep patterns may contribute to the reduction of the burden of cardiovascular diseases.

Atherosclerotic burden (3DVUS) & sleep

Please login to My ESC

This content may be restricted, please sign in to check your access.

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are